Base de dados : MEDLINE
Pesquisa : D12.776.157.530.450.074.500 [Categoria DeCS]
Referências encontradas : 2990 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 299 ir para página                         

  1 / 2990 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468836
[Au] Autor:Yoshikado T; Toshimoto K; Nakada T; Ikejiri K; Kusuhara H; Maeda K; Sugiyama Y
[Ad] Endereço:Sugiyama Laboratory, RIKEN Innovation Center, RIKEN, Kanagawa, Japan (T.Y., K.T., Y.S.); DMPK Research Laboratories Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma, Saitama, Japan (T.N.); and Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Univer
[Ti] Título:Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using Statins.
[So] Source:Drug Metab Dispos;45(7):779-789, 2017 Jul.
[Is] ISSN:1521-009X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:It is essential to estimate concentrations of unbound drugs inside the hepatocytes to predict hepatic clearance, efficacy, and toxicity of the drugs. The present study was undertaken to compare predictability of the unbound hepatocyte-to-medium concentration ratios (K ) by two methods based on the steady-state cell-to-medium total concentration ratios at 37°C and on ice (K ) and based on their initial uptake rates (K ). Poorly metabolized statins were used as test drugs because of their concentrative uptake via organic anion-transporting polypeptides. K values of these statins provided less interexperimental variation than the K values, because only data at longer time are required for K K values for pitavastatin, rosuvastatin, and pravastatin were 1.2- to 5.1-fold K in rat hepatocytes; K values in human hepatocytes also tended to be larger than corresponding K To explain these discrepancies, theoretical values of K and K were compared with true K (K ), considering the inside-negative membrane potential and ionization of the drugs in hepatocytes and medium. Membrane potentials were approximately -30 mV in human hepatocytes at 37°C and almost abolished on ice. Theoretical equations considering the membrane potentials indicate that K values for the statins are 0.85- to 1.2-fold K , whereas K values are 2.2- to 3.1-fold K , depending on the ratio of the passive permeability of the ionized to nonionized forms. In conclusion, K values of anions are similar to K when the inside-negative membrane potential is considered. This suggests that K is preferable for estimating the concentration of unbound drugs inside the hepatocytes.
[Mh] Termos MeSH primário: Hepatócitos/metabolismo
Inibidores de Hidroximetilglutaril-CoA Redutases/metabolismo
[Mh] Termos MeSH secundário: Animais
Transporte Biológico/fisiologia
Seres Humanos
Fígado/metabolismo
Masculino
Potenciais da Membrana/fisiologia
Transportadores de Ânions Orgânicos/metabolismo
Permeabilidade
Pravastatina/metabolismo
Quinolinas/metabolismo
Ratos
Ratos Sprague-Dawley
Rosuvastatina Cálcica/metabolismo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Organic Anion Transporters); 0 (Quinolines); 83MVU38M7Q (Rosuvastatin Calcium); KXO2KT9N0G (Pravastatin); M5681Q5F9P (pitavastatin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1124/dmd.116.074823


  2 / 2990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29318274
[Ti] Título:Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia.
[So] Source:JAMA;319(2):188-189, 2018 01 09.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Alopurinol/administração & dosagem
Supressores da Gota/uso terapêutico
Gota/tratamento farmacológico
Hiperuricemia/tratamento farmacológico
Tioglicolatos/administração & dosagem
Tioglicolatos/uso terapêutico
Triazóis/administração & dosagem
[Mh] Termos MeSH secundário: Alopurinol/efeitos adversos
Alopurinol/uso terapêutico
Combinação de Medicamentos
Interações Medicamentosas
Gota/complicações
Supressores da Gota/efeitos adversos
Seres Humanos
Hiperuricemia/complicações
Transportadores de Ânions Orgânicos/antagonistas & inibidores
Proteínas de Transporte de Cátions Orgânicos/antagonistas & inibidores
Tioglicolatos/efeitos adversos
Triazóis/efeitos adversos
Xantina Oxidase/antagonistas & inibidores
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Duzallo); 0 (Gout Suppressants); 0 (Organic Anion Transporters); 0 (Organic Cation Transport Proteins); 0 (SLC22A12 protein, human); 0 (Thioglycolates); 0 (Triazoles); 09ERP08I3W (lesinurad); 63CZ7GJN5I (Allopurinol); EC 1.17.3.2 (Xanthine Oxidase)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.20189


  3 / 2990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27777271
[Au] Autor:Lee HH; Leake BF; Kim RB; Ho RH
[Ad] Endereço:Division of Hematology and Oncology, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee (H.H.L., B.F.L., R.H.H.); and Division of Clinical Pharmacology, Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Can
[Ti] Título:Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance.
[So] Source:Mol Pharmacol;91(1):14-24, 2017 Jan.
[Is] ISSN:1521-0111
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The organic anion-transporting polypeptides represent an important family of drug uptake transporters that mediate the cellular uptake of a broad range of substrates including numerous drugs. Doxorubicin is a highly efficacious and well-established anthracycline chemotherapeutic agent commonly used in the treatment of a wide range of cancers. Although doxorubicin is a known substrate for efflux transporters such as P-glycoprotein (P-gp; MDR1, ABCB1), significantly less is known regarding its interactions with drug uptake transporters. Here, we investigated the role of organic anion transporting polypeptide (OATP) transporters to the disposition of doxorubicin. A recombinant vaccinia-based method for expressing uptake transporters in HeLa cells revealed that OATP1A2, but not OATP1B1 or OATP1B3, and the rat ortholog Oatp1a4 were capable of significant doxorubicin uptake. Interestingly, transwell assays using Madin-Darby canine kidney II cell line cells stably expressing specific uptake and/or efflux transporters revealed that OATP1B1, OATP1B3, and OATP1A2, either alone or in combination with MDR1, significantly transported doxorubicin. An assessment of polymorphisms in SLCO1A2 revealed that four variants were associated with significantly impaired doxorubicin transport in vitro. In vivo doxorubicin disposition studies revealed that doxorubicin plasma area under the curve was significantly higher (1.7-fold) in Slco1a/1b versus wild-type mice. The liver-to-plasma ratio of doxorubicin was significantly decreased (2.3-fold) in Slco1a/1b2 mice and clearance was reduced by 40% compared with wild-type mice, suggesting Oatp1b transporters are important for doxorubicin hepatic uptake. In conclusion, we demonstrate important roles for OATP1A/1B in transporter-mediated uptake and disposition of doxorubicin.
[Mh] Termos MeSH primário: Doxorrubicina/metabolismo
Transportadores de Ânions Orgânicos Sódio-Independentes/metabolismo
Transportadores de Ânions Orgânicos/metabolismo
Proteínas de Transporte de Cátions Orgânicos/metabolismo
[Mh] Termos MeSH secundário: Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo
Animais
Transporte Biológico
Membrana Celular/metabolismo
Cães
Células HeLa
Seres Humanos
Cinética
Fígado/metabolismo
Células Madin Darby de Rim Canino
Masculino
Camundongos
Modelos Biológicos
Proteínas Mutantes/metabolismo
Ratos
Transfecção
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ATP-Binding Cassette, Sub-Family B, Member 1); 0 (Mutant Proteins); 0 (Oatp1a1 protein, mouse); 0 (Organic Anion Transporters); 0 (Organic Anion Transporters, Sodium-Independent); 0 (Organic Cation Transport Proteins); 0 (SLCO1A2 protein, human); 0 (Slco1b2 protein, mouse); 80168379AG (Doxorubicin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:180101
[Lr] Data última revisão:
180101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  4 / 2990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28982888
[Au] Autor:Morine Y; Enkhbold C; Imura S; Ikemoto T; Iwahashi S; Saito YU; Yamada S; Utsunomiya T; Shimada M
[Ad] Endereço:Department of Surgery, Institute of Biochemical Sciences, Tokushima University Graduate School, Tokushima, Japan ymorine@tokushima-u.ac.jp.
[Ti] Título:Accurate Estimation of Functional Liver Volume Using Gd-EOB-DTPA MRI Compared to MDCT/ Tc-SPECT Fusion Imaging.
[So] Source:Anticancer Res;37(10):5693-5700, 2017 10.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: We assessed the utility of dynamic magnetic resonance imaging (MRI) with gadoxetate-ethoxybenzyl-diethylenetriamine penta-aceticpenta-acetic acid (Gd-EOB-DTPA) (EOB-MRI) for estimating functional liver volume compared to Tc-galactosyl albumin single-photon-emission computed tomography ( Tc-GSA SPECT). PATIENTS AND METHODS: Regional functional liver volume (left lateral, medial, right anterior, right posterior) of 58 hepatectomized patients was assessed using EOB-MRI and Tc-GSA SPECT, and compared to the actual liver volume with MDCT-3D volumetry. RESULTS: Tc-GSA SPECT found a significantly lower functional volume of the left lateral section than the actual volume found by MDCT-3D volumetry (p=0.003) and EOB-MRI (p<0.001). Functional liver volume of right anterior section found with Tc-GSA SPECT was significantly higher than that found by MDCT-3D volumetry (p=0.04), despite no differences in asialoglycoprotein receptor 1 (ASGR1) or ATP-dependent organic anion transporting polypeptide 1 (OATP) expression between the left lateral and right anterior sections. CONCLUSION: Tc-GSA SPECT might underestimate the function of the left lobe and overestimate that of the right lobe. Therefore, EOB-MRI could be better for estimating the true regional functional liver reserve.
[Mh] Termos MeSH primário: Meios de Contraste/administração & dosagem
Gadolínio DTPA/administração & dosagem
Fígado/diagnóstico por imagem
Imagem por Ressonância Magnética/métodos
Tomografia Computadorizada Multidetectores
Compostos Radiofarmacêuticos/administração & dosagem
Tomografia Computadorizada com Tomografia Computadorizada de Emissão de Fóton Único/métodos
Agregado de Albumina Marcado com Tecnécio Tc 99m/administração & dosagem
Pentetato de Tecnécio Tc 99m/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Receptor de Asialoglicoproteína/análise
Biomarcadores/análise
Biópsia
Feminino
Hepatectomia
Seres Humanos
Imuno-Histoquímica
Fígado/química
Fígado/cirurgia
Masculino
Meia-Idade
Tamanho do Órgão
Transportadores de Ânions Orgânicos/análise
Valor Preditivo dos Testes
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ASGR1 protein, human); 0 (Asialoglycoprotein Receptor); 0 (Biomarkers); 0 (Contrast Media); 0 (Organic Anion Transporters); 0 (Radiopharmaceuticals); 0 (SLCO1A2 protein, human); 0 (Technetium Tc 99m Aggregated Albumin); 0 (gadolinium ethoxybenzyl DTPA); 0 (technetium Tc 99m DTPA-galactosyl-human serum albumin); K2I13DR72L (Gadolinium DTPA); VW78417PU1 (Technetium Tc 99m Pentetate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171007
[St] Status:MEDLINE


  5 / 2990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28938430
[Au] Autor:Kersseboom S; van Gucht ALM; van Mullem A; Brigante G; Farina S; Carlsson B; Donkers JM; van de Graaf SFJ; Peeters RP; Visser TJ
[Ad] Endereço:Department of Internal Medicine and Rotterdam Thyroid Center, Erasmus University Medical Center, 3015 GE Rotterdam, The Netherlands.
[Ti] Título:Role of the Bile Acid Transporter SLC10A1 in Liver Targeting of the Lipid-Lowering Thyroid Hormone Analog Eprotirome.
[So] Source:Endocrinology;158(10):3307-3318, 2017 Oct 01.
[Is] ISSN:1945-7170
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The thyroid hormone (TH) analog eprotirome (KB2115) was developed to lower cholesterol through selective activation of the TH receptor (TR) ß1 in the liver. Interestingly, eprotirome shows low uptake in nonhepatic tissues, explaining its lipid-lowering action without adverse extrahepatic thyromimetic effects. Clinical trials have shown marked decreases in serum cholesterol levels. We explored the transport of eprotirome across the plasma membrane by members of three TH transporter families: monocarboxylate transporters MCT8 and MCT10; Na-independent organic anion transporters 1A2, 1B1, 1B3, 1C1, 2A1, and 2B1; and Na-dependent organic anion transporters SLC10A1 to SLC10A7. Cellular transport was studied in transfected COS1 cells using [14C]eprotirome and [125I]TH analogs. Of the 15 transporters tested initially, the liver-specific bile acid transporter SLC10A1 showed the highest eprotirome uptake (greater than a sevenfold induction after 60 minutes) as well as TRß1-mediated transcriptional activity. Uptake of eprotirome by SLC10A1 was Na+ dependent and saturable with a Michaelis constant of 8 µM. Eprotirome transport was inhibited by known substrates for SLC10A1 (e.g., cholate and taurocholate), and by TH analogs such as triiodothyropropionic acid and triiodothyroacetic acid. However, no significant SLC10A1-mediated transport was observed of these [125I]TH analogs. We also studied the plasma disappearance and biliary excretion of [14C]eprotirome injected in control and Slc10a1 knockout mice. Although eprotirome is also transported by mouse Slc10a1, the pharmacokinetics of eprotirome were not affected by Slc10a1 deficiency. In conclusion, we have demonstrated that the liver-specific bile acid transporter SLC10A1 effectively transports eprotirome. However, Slc10a1 does not appear to be critical for the liver targeting of this TH analog in mice. Therefore, the importance of SLC10A1 for liver uptake of eprotirome in humans remains to be elucidated.
[Mh] Termos MeSH primário: Anilidas/farmacologia
Anilidas/farmacocinética
Anticolesterolemiantes
Fígado/efeitos dos fármacos
Transportadores de Ânions Orgânicos Dependentes de Sódio/fisiologia
Simportadores/fisiologia
[Mh] Termos MeSH secundário: Animais
Transporte Biológico
Células COS
Membrana Celular/metabolismo
Cercopithecus aethiops
Seres Humanos
Fígado/metabolismo
Camundongos
Camundongos Knockout
Terapia de Alvo Molecular
Transportadores de Ácidos Monocarboxílicos/metabolismo
Transportadores de Ânions Orgânicos/metabolismo
Transportadores de Ânions Orgânicos Dependentes de Sódio/deficiência
Transportadores de Ânions Orgânicos Dependentes de Sódio/genética
RNA Mensageiro/análise
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Sódio/farmacologia
Simportadores/deficiência
Simportadores/genética
Hormônios Tireóideos/metabolismo
Transfecção
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid); 0 (Anilides); 0 (Anticholesteremic Agents); 0 (Monocarboxylic Acid Transporters); 0 (Organic Anion Transporters); 0 (Organic Anion Transporters, Sodium-Dependent); 0 (RNA, Messenger); 0 (Symporters); 0 (Thyroid Hormones); 145420-23-1 (sodium-bile acid cotransporter); 9NEZ333N27 (Sodium)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170923
[St] Status:MEDLINE
[do] DOI:10.1210/en.2017-00433


  6 / 2990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28890383
[Au] Autor:Yuan Y; Yang H; Kong L; Li Y; Li P; Zhang H; Ruan J
[Ad] Endereço:College of Pharmaceutical Sciences, Soochow University, Suzhou, China; Department of Pharmacy, Wuxi Maternity and Child Health Hospital Affiliated to Nanjing Medical University, Wuxi, China.
[Ti] Título:Interaction between rhein acyl glucuronide and methotrexate based on human organic anion transporters.
[So] Source:Chem Biol Interact;277:79-84, 2017 Nov 01.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Rhein, a major bioactive compound of many medicinal herbs and the prodrug of diacerein, is often used with low dose of methotrexate as drug combination to treat rheumatoid arthritis. In this study, potential drug-drug interaction between methotrexate and rhein was investigated based on organic anion transporters (OAT). Our study demonstrated that rhein acyl glucuronide (RAG), the major metabolite of rhein in the human blood circulation, significantly inhibited the uptake of p-aminohippurate in hOAT1 transfected cells with IC value of 691 nM and estrone sulfate uptake in hOAT3 transfected cells with IC value of 78.5 nM. As the substrate of both hOAT1 and hOAT3, the methotrexate transport was significantly inhibited by RAG in hOAT1 transfected cells at 50 µM and hOAT3 transfected cells at 1 µM by 69% and 87%, respectively. Further in vivo study showed that after co-administrated with RAG in rats the AUC values of methotrexate increased from 3109 to 5370 ng/mL*hr and the t was prolonged by 40.5% (from 7.4 to 10.4 h), demonstrating the inhibitory effect of RAG on methotrexate excretion. In conclusion, rhein acyl glucuronide could significantly decrease the transport of methotrexate by both hOAT1 and hOAT3. The combination use of rhein, diacerein or other rhein-containing herbs with methotrexate may cause obvious drug-drug interaction and require close monitoring for potential drug interaction in clinical practice.
[Mh] Termos MeSH primário: Antraquinonas/farmacologia
Antirreumáticos/farmacocinética
Inibidores Enzimáticos/farmacologia
Glucuronídeos/farmacologia
Metotrexato/farmacocinética
Transportadores de Ânions Orgânicos/antagonistas & inibidores
[Mh] Termos MeSH secundário: Animais
Antraquinonas/metabolismo
Interações Medicamentosas
Inibidores Enzimáticos/metabolismo
Glucuronídeos/metabolismo
Células HEK293
Seres Humanos
Masculino
Proteína 1 Transportadora de Ânions Orgânicos/antagonistas & inibidores
Proteína 1 Transportadora de Ânions Orgânicos/metabolismo
Transportadores de Ânions Orgânicos/metabolismo
Transportadores de Ânions Orgânicos Sódio-Independentes/antagonistas & inibidores
Transportadores de Ânions Orgânicos Sódio-Independentes/metabolismo
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anthraquinones); 0 (Antirheumatic Agents); 0 (Enzyme Inhibitors); 0 (Glucuronides); 0 (Organic Anion Transport Protein 1); 0 (Organic Anion Transporters); 0 (Organic Anion Transporters, Sodium-Independent); 0 (SLC22A7 protein, human); YL5FZ2Y5U1 (Methotrexate); YM64C2P6UX (rhein)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170912
[St] Status:MEDLINE


  7 / 2990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28783044
[Au] Autor:Ware JS; Wain LV; Channavajjhala SK; Jackson VE; Edwards E; Lu R; Siew K; Jia W; Shrine N; Kinnear S; Jalland M; Henry AP; Clayton J; O'Shaughnessy KM; Tobin MD; Schuster VL; Cook S; Hall IP; Glover M
[Ad] Endereço:NIHR Biomedical Research Unit in Cardiovascular Disease at Royal Brompton & Harefield, NHS Foundation Trust and Imperial College London, London, United Kingdom.
[Ti] Título:Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia.
[So] Source:J Clin Invest;127(9):3367-3374, 2017 Sep 01.
[Is] ISSN:1558-8238
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Thiazide diuretics are among the most widely used treatments for hypertension, but thiazide-induced hyponatremia (TIH), a clinically significant adverse effect, is poorly understood. Here, we have studied the phenotypic and genetic characteristics of patients hospitalized with TIH. In a cohort of 109 TIH patients, those with severe TIH displayed an extended phenotype of intravascular volume expansion, increased free water reabsorption, urinary prostaglandin E2 excretion, and reduced excretion of serum chloride, magnesium, zinc, and antidiuretic hormone. GWAS in a separate cohort of 48 TIH patients and 2,922 controls from the 1958 British birth cohort identified an additional 14 regions associated with TIH. We identified a suggestive association with a variant in SLCO2A1, which encodes a prostaglandin transporter in the distal nephron. Resequencing of SLCO2A1 revealed a nonsynonymous variant, rs34550074 (p.A396T), and association with this SNP was replicated in a second cohort of TIH cases. TIH patients with the p.A396T variant demonstrated increased urinary excretion of prostaglandin E2 and metabolites. Moreover, the SLCO2A1 phospho-mimic p.A396E showed loss of transporter function in vitro. These findings indicate that the phenotype of TIH involves a more extensive metabolic derangement than previously recognized. We propose one mechanism underlying TIH development in a subgroup of patients in which SLCO2A1 regulation is altered.
[Mh] Termos MeSH primário: Hiponatremia/induzido quimicamente
Inibidores de Simportadores de Cloreto de Sódio/efeitos adversos
Tiazidas/efeitos adversos
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Aquaporina 1/genética
Aquaporina 2/genética
Estudos de Coortes
Dinoprostona/metabolismo
Feminino
Estudo de Associação Genômica Ampla
Seres Humanos
Hiponatremia/genética
Masculino
Meia-Idade
Néfrons/metabolismo
Transportadores de Ânions Orgânicos/genética
Farmacogenética
Fenótipo
Polimorfismo de Nucleotídeo Único
Prostaglandinas/metabolismo
Reino Unido
Água/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (AQP1 protein, human); 0 (AQP2 protein, human); 0 (Aquaporin 2); 0 (Organic Anion Transporters); 0 (Prostaglandins); 0 (SLCO2A1 protein, human); 0 (Sodium Chloride Symporter Inhibitors); 0 (Thiazides); 059QF0KO0R (Water); 146410-94-8 (Aquaporin 1); K7Q1JQR04M (Dinoprostone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170808
[St] Status:MEDLINE


  8 / 2990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28762529
[Au] Autor:Harshman LC; Werner L; Tripathi A; Wang X; Maughan BL; Antonarakis ES; Nakabayashi M; McKay R; Pomerantz M; Mucci LA; Taplin ME; Sweeney CJ; Lee GM; Kantoff PW
[Ad] Endereço:Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
[Ti] Título:The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.
[So] Source:Prostate;77(13):1303-1311, 2017 May.
[Is] ISSN:1097-0045
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Statins compete with DHEAS for influx through the SLCO2B1 transporter, which may prolong time to progression (TTP) on androgen deprivation therapy. Abiraterone acetate (AA) may also undergo SLCO-mediated transport. Based on preclinical findings showing antagonism, we hypothesized that statins may compete with AA for influx via SLCO2B1 and could negatively impact drug efficacy. METHODS: We queried two institutional clinical databases (Dana-Farber Cancer Institute [DFCI], Johns Hopkins University [JHU]) for CRPC patients treated with AA. Treatment duration was a surrogate for TTP. Associations between statin use and AA duration were estimated using the Kaplan-Meier method. Multivariable Cox regression modeling adjusted for known prognostic factors. RESULTS: Of the 224 DFCI and 270 JHU patients included, the majority (96%) had metastatic disease. Nearly half (41% and 45%) were statin users. In the DFCI cohort, there was a trend toward longer AA duration in statin users: 14.2 versus 9.2 months (HR 0.79, 95%CI: 0.57-1.09, P = 0.14). There was no association between statin use and AA duration in the JHU cohort: 8.3 versus 8.0 months (HR 0.89, 95%CI: 0.69-1.16, P = 0.38) in the statin users versus non-users, except for a trend in patients that had not previously received docetaxel or enzalutamide (HR 0.79; 95%CI: 0.57-1.10). CONCLUSIONS: Contrary to our initial hypothesis, there was a trend toward longer (rather than shorter) AA duration in statin users in the entire DFCI cohort and in the enzalutamide- and docetaxel-naïve JHU patients. Together, these results do not support the hypothesis that statins interfere with AA efficacy.
[Mh] Termos MeSH primário: Acetato de Abiraterona
Transporte Biológico/efeitos dos fármacos
Inibidores de Hidroximetilglutaril-CoA Redutases
Transportadores de Ânions Orgânicos/metabolismo
Neoplasias de Próstata Resistentes à Castração
[Mh] Termos MeSH secundário: Acetato de Abiraterona/administração & dosagem
Acetato de Abiraterona/farmacocinética
Idoso
Antineoplásicos/administração & dosagem
Antineoplásicos/farmacocinética
Antineoplásicos/uso terapêutico
Linhagem Celular
Progressão da Doença
Sinergismo Farmacológico
Registros Eletrônicos de Saúde/estatística & dados numéricos
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem
Inibidores de Hidroximetilglutaril-CoA Redutases/farmacocinética
Masculino
Meia-Idade
Feniltioidantoína/análogos & derivados
Feniltioidantoína/uso terapêutico
Antígeno Prostático Específico/análise
Neoplasias de Próstata Resistentes à Castração/tratamento farmacológico
Neoplasias de Próstata Resistentes à Castração/metabolismo
Neoplasias de Próstata Resistentes à Castração/patologia
Estudos Retrospectivos
Taxoides/uso terapêutico
Fatores de Tempo
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (MDV 3100); 0 (Organic Anion Transporters); 0 (SLCO2B1 protein, human); 0 (Taxoids); 15H5577CQD (docetaxel); 2010-15-3 (Phenylthiohydantoin); EC 3.4.21.77 (Prostate-Specific Antigen); EM5OCB9YJ6 (Abiraterone Acetate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171111
[Lr] Data última revisão:
171111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170802
[St] Status:MEDLINE
[do] DOI:10.1002/pros.23390


  9 / 2990 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28724612
[Au] Autor:Prestin K; Hussner J; Ferreira C; Seibert I; Breitung V; Zimmermann U; Meyer Zu Schwabedissen HE
[Ad] Endereço:Department of Pharmaceutical Sciences, Biopharmacy, University of Basel, Basel, Switzerland; and.
[Ti] Título:Regulation of PDZ domain-containing 1 (PDZK1) expression by hepatocyte nuclear factor-1α (HNF1α) in human kidney.
[So] Source:Am J Physiol Renal Physiol;313(4):F973-F983, 2017 Oct 01.
[Is] ISSN:1522-1466
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In the renal proximal tubule the secretion and reabsorption of glomerularly filtrated compounds is realized by a functional network of uptake and efflux transporters. The activity and localization of several transporters expressed at the apical tubular membrane are regulated by the membrane-associated protein PDZ domain-containing 1 (PDZK1). We aimed to characterize the transcriptional regulation of this modulator of renal transport. Coexpression analyses of PDZK1 and putative regulators were performed using human kidney samples. Protein and mRNA expression of PDZK1 in renal proximal tubule epithelial cells after adenoviral transfer and siRNA knockdown of transcription factor hepatocyte nuclear factor-1α (HNF1α) was assessed by quantitative real-time PCR and Western blot analysis. Transactivation of the PDZK1 promoter was quantified in cell-based reporter gene assays. Subsequently, the binding of HNF1α to the PDZK1 promoter was verified by in silico analyses and chromatin immunoprecipitation assay. HNF1α positively regulated the promoter activity of PDZK1. Adenoviral overexpression of HNF1α in renal proximal tubule epithelial cells (RPTEC) increased PDZK1 mRNA and protein expression, whereas siRNA knockdown of HNF1α resulted in decreased expression of PDZK1. Our results show that HNF1α, which has previously been described as a modulator of several transporters of the renal transportosome, is also a key determinant of PDZK1 transcription.
[Mh] Termos MeSH primário: Proteínas de Transporte/metabolismo
Regulação da Expressão Gênica
Fator 1-alfa Nuclear de Hepatócito/metabolismo
Rim/metabolismo
[Mh] Termos MeSH secundário: Proteínas de Transporte/genética
Células HeLa
Seres Humanos
Transportadores de Ânions Orgânicos/metabolismo
Regiões Promotoras Genéticas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Carrier Proteins); 0 (HNF1A protein, human); 0 (Hepatocyte Nuclear Factor 1-alpha); 0 (Organic Anion Transporters); 0 (PDZK1 protein, human); 0 (urate transporter)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170721
[St] Status:MEDLINE
[do] DOI:10.1152/ajprenal.00650.2016


  10 / 2990 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28673128
[Au] Autor:Fukui K; Nanatani K; Hara Y; Yamakami S; Yahagi D; Chinen A; Tokura M; Abe K
[Ad] Endereço:a Frontier Research Laboratories , Institute for Innovation, Ajinomoto Co., Inc. , Kawasaki-ku , Japan.
[Ti] Título:Escherichia coli yjjPB genes encode a succinate transporter important for succinate production.
[So] Source:Biosci Biotechnol Biochem;81(9):1837-1844, 2017 Sep.
[Is] ISSN:1347-6947
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Under anaerobic conditions, Escherichia coli produces succinate from glucose via the reductive tricarboxylic acid cycle. To date, however, no genes encoding succinate exporters have been established in E. coli. Therefore, we attempted to identify genes encoding succinate exporters by screening an E. coli MG1655 genome library. We identified the yjjPB genes as candidates encoding a succinate transporter, which enhanced succinate production in Pantoea ananatis under aerobic conditions. A complementation assay conducted in Corynebacterium glutamicum strain AJ110655ΔsucE1 demonstrated that both YjjP and YjjB are required for the restoration of succinate production. Furthermore, deletion of yjjPB decreased succinate production in E. coli by 70% under anaerobic conditions. Taken together, these results suggest that YjjPB constitutes a succinate transporter in E. coli and that the products of both genes are required for succinate export.
[Mh] Termos MeSH primário: Proteínas de Escherichia coli/genética
Proteínas de Escherichia coli/metabolismo
Escherichia coli/genética
Escherichia coli/metabolismo
Transportadores de Ânions Orgânicos/genética
Transportadores de Ânions Orgânicos/metabolismo
Ácido Succínico/metabolismo
[Mh] Termos MeSH secundário: Anaerobiose
Corynebacterium glutamicum/genética
Teste de Complementação Genética
Alinhamento de Sequência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Escherichia coli Proteins); 0 (Organic Anion Transporters); 0 (YjjB protein, E coli); 0 (YjjP protein, E coli); AB6MNQ6J6L (Succinic Acid)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170705
[St] Status:MEDLINE
[do] DOI:10.1080/09168451.2017.1345612



página 1 de 299 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde